New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
11:15 EDTGHDXGenomic Health Oncotype DX recommended in NICE guidance
The U.K.'s National Institute for Health and Clinical Excellence, or NICE, issued draft guidance on four tests used to guide decisions about the use of chemotherapy in people with early breast cancer following consultations on previous drafts and the submission of a confidential access proposal by the manufacturer of Oncotype DX, Genomic Health (GHDX). The draft guidance recommends the use of Oncotype DX in people with oestrogen receptor positive, lymph node negative and human epidermal growth factor receptor 2 negative early breast cancer, who are assessed as being at intermediate risk, to guide chemotherapy decisions where the manufacturer provides it at the price offered through the confidential access proposal. The recommendation for Oncotype DX applies to people assessed as being at intermediate risk of distant recurrence by decision making tools/protocols currently in use in the NHS and where the decision to prescribe chemotherapy remains unclear, NICE said. The draft guidance also highlights that it has not been able to support the routine use of the IHC4, MammaPrint or Mammostrat tests but recommends that they are used in a research setting to collect evidence about potentially important clinical outcomes and to determine the ability of the tests to predict the efficacy of chemotherapy in people with early breast cancer. Reference Link
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 19, 2014
08:05 EDTGHDXGenomic Health reports publication of results from second Oncotype DX validation
Genomic Health announced multiple upcoming presentations at the 2014 Society of Urologic Oncology Annual Meeting, including the second large, independent clinical validation study of the Oncotype DX prostate cancer test and results from the first prostate cancer decision impact study. The results from the latest validation study of the test, conducted in collaboration with the Center for Prostate Disease Research, have been accepted for publication in European Urology. Separately, the results of the first decision impact study of the Oncotype DX prostate cancer test, conducted in collaboration with academic and community practices at Columbia University, Delaware Valley Urology and Orange County Urology, have been accepted for publication in Urology Practice, an official journal of the American Urological Association. Additionally, Genomic Health will present results from its first liquid biopsy study assessing multiple technologies, including next-generation sequencing, for their ability to detect and analyze the presence of bladder cancer in urine.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use